Amanta Healthcare IPO: Full Details, Dates, Review & Should You Apply?

The primary market is buzzing again, and the Amanta Healthcare IPO adds a healthcare play to the calendar. Amanta is a long-standing manufacturer of sterile liquid pharmaceuticals with advanced ABFS and ISBM technologies, a broad domestic network, and registrations across global markets. If you are evaluating new issues for listing gains or a potential long-term hold, this structured review of the Amanta Healthcare IPO compiles every key fact from the company’s materials—without changing any stats or meanings—and presents them in a synchronized, investor-friendly sequence.

Amanta Healthcare IPO: Timeline & Key Terms

• IPO Open Date: September 1, 2025
  
• IPO Close Date: September 3, 2025
  
• Proposed Listing Date: September 9, 2025
  
• Face Value: ₹10 per share
  
• Price Band: ₹120 to ₹126 per share
  
• Lot Size: 119 shares
  
• Issue Size: 1,00,00,000 shares (aggregating up to ₹126.00 crore)
  
• Type of Issue:Fresh Capital

These Amanta Healthcare IPO terms set the base for applications, risk budgeting, and potential listing strategies.

Amanta Healthcare IPO: What the Company Does

Amanta Healthcare develops, produces, and markets a diverse portfolio of sterile liquid products, primarily parenteral formulations. Its range spans large volume parenterals (LVPs) and small volume parenterals (SVPs) across six therapeutic segments, along with IV fluids, diluents, ophthalmic solutions, respiratory care, irrigation solutions, first-aid products, and eye lubricants.

The company offers multiple closure systems—nipple head, twist-off, leur-lock, and screw types—across container fill-volumes from 2 ml to 1000 ml, serving varied clinical needs. Amanta operates through three strategic business units: national sales, international sales, and product partnering.

Domestically, it markets 45+ generic products via a distribution network of more than 320 distributors and stockists. Internationally, it shows long operating experience with 47 products registered in 120 jurisdictions and exports to 21 countries, which reduces market concentration risk and supports recurring business.

Amanta Healthcare IPO: Manufacturing, Certifications & Capacity

The company’s formulation & development (F&D) and quality control laboratory are located at Hariyala, District Kheda, Gujarat. The manufacturing setup comprises:

• Four LVP lines — two with ABFS technology for conventional single-port containers and two ISBM lines for SteriPort products.
  
• Three SVP lines — two ABFS lines and one conventional three-piece filling line.

Amanta adheres to stringent quality systems. It holds GMP certifications from the Food & Drugs Control Administration, Gujarat (in line with WHO-recommended formats), GMP approvals from regulators in Cambodia, Sudan, the Philippines, and Zimbabwe, and a DNV certificate for exports of medical device products. In FY 2025, the company reported high capacity utilization of 96%, reflecting demand as well as operational efficiency.

Amanta Healthcare IPO: Financial Performance (FY23–FY25)

From the company’s reported numbers (₹ crore):

Two points stand out for the Amanta Healthcare IPO lens: (1) a clear turnaround at the net level from a loss in FY23 to profit in FY24 and double-digit PAT (₹10.50 crore) in FY25, and (2) EBITDA improving to ₹61.05 crore in FY25 with margins above 20%. Reported revenues were ₹27,470.82 lakhs in FY25, showing stable scale while maintaining operating discipline.

Amanta Healthcare IPO: Key Ratios & What They Signal

• ROE: 12.42%
  
• ROCE: 13.72%
  
• Debt/Equity: 2.02 (reduced from 3.43 in FY23)
  
• RoNW: 10.89%
  
• PAT Margin: 3.86%
  
• EBITDA Margin: 22.11%
  
• Price to Book Value:3.77

For investors tracking the Amanta Healthcare IPO, these ratios show improving profitability and capital efficiency alongside a deleveraging trend. ROE/ROCE in double digits, coupled with a lower debt/ equity ratio relative to FY23, indicates healthier balance-sheet optics.

Amanta Healthcare IPO: Investment Rationale (Strengths)

• Established since 1994 with a diversified sterile-liquids portfolio across six therapeutic segments, aiding business stability.
  
• Global footprint: 47 products registered in 120 jurisdictions with exports to 21 countries.
  
• Advanced manufacturing in Gujarat using ABFS and ISBM technologies for scalable and efficient production.
  
• 96% capacity utilization in FY 2025, reflecting strong demand.
  
• Multiple certifications: ISO, WHO-GMP, and approvals from international bodies, enabling access to regulated/semi-regulated markets.
  
• Robust domestic network: 320+ distributors/stockists supported by a 96-member sales team.
  
• Partnering & contract manufacturing model with leading Indian and global pharma companies, supporting predictable/recurring revenue.
  
• Customized formulation and development capabilities that drive customer retention and portfolio expansion.
  
• Stable revenues of ₹27,470.82 lakhs (FY25) with EBITDA margins above 20%.
  
• Profitability improvement: PAT rose from ₹363.32 lakhs (FY24) to ₹1,050.07 lakhs (FY25).
  
• Financial strengthening: Debt/Equity down from 3.43 (FY23) to 2.02 (FY25) with healthy ROE 12.42% and ROCE 13.72%.
  
• Experienced leadership: Promoter & MD Bhavesh Patel; workforce of 500+ skilled employees.
  
• Strategic focus on capacity expansion and new product development.
  
• Strong compliance with cGMP and quality assurance standards.

These strengths outline why the Amanta Healthcare IPO is positioned as a credible healthcare manufacturing story.

Amanta Healthcare IPO: Risks & Challenges to Track

• Ongoing legal and regulatory proceedings; adverse outcomes could affect business, reputation, and financials.
  
• Dependence on the Indian economic environment and exposure to global macro swings.
  
• High finance costs have historically formed a significant portion of EBITDA; interest-rate scenarios matter for future projects.
  
• Labor-intensive operations bring risks of strikes, stoppages, wage demands, and the company has faced high attrition earlier.
  
• Single-location manufacturing concentration at Hariyala, Gujarat increases vulnerability to disruptions, accidents, or natural events.
  
• Competitive industry dynamics with regional/multinational peers can pressure prices and demand.
  
• Export exposure introduces legal, economic, and FX risks.

A prudent view of the Amanta Healthcare IPO should incorporate these risks alongside the growth triggers.

Amanta Healthcare IPO: Objects of the Issue & Use of Proceeds

• ₹70 crore: Capex for civil construction and purchase of equipment/plant & machinery to set up a new SteriPort manufacturing line at Hariyala, Kheda, Gujarat.
  
• ₹30.13 crore: Capex for civil construction and purchase of equipment/plant & machinery to set up a new SVP manufacturing line at Hariyala, Kheda, Gujarat.
  
• Balance:General corporate purposes.

These allocations directly align the Amanta Healthcare IPO with capacity expansion and operational strengthening to serve demand in domestic and international markets.

Amanta Healthcare IPO: How an Investor May Evaluate It

For short-term participants, the combination of established operations, improving profit trajectory, and capacity-led growth supports the case for potential listing gains—subject to overall market conditions. For long-term investors, the Amanta Healthcare IPO offers exposure to sterile-liquid pharmaceuticals with certification-led access to global markets and a deleveraging balance sheet. On the flip side, investors should remain mindful of finance-cost sensitivity, single-site concentration, and sector competition while allocating capital.

Amanta Healthcare IPO: Apply or Avoid

Based on the company-shared information, the house view is to Subscribe for listing gains, and investors can also hold for the long term, provided their risk tolerance accommodates the noted challenges (legal/regulatory exposure, borrowing-cost profile, and single-location risk). The Amanta Healthcare IPO thus suits investors looking for a healthcare manufacturing story with visible expansion use-cases.